Corticobasal Degeneration (Cbd) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Corticobasal Degeneration (CBD), also known as corticobasal syndrome (CBS), is a rare but progressively disabling neurodegenerative disorder characterized by asymmetric
parkinsonism, apraxia, cortical sensory loss, and alien limb phenomena [1]. CBD is classified as a tauopathy, sharing pathological features with
Progressive Supranuclear Palsy (PSP) but with a distinct clinical presentation and distribution of pathology [2].
The disease was first described in 1968 by Rebeiz and colleagues as "corticodentatonigral degeneration with neuronal achromasia" based on the neuropathological findings of cortical and basal ganglia degeneration with characteristic ballooned, achromatic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--. The clinical syndrome, termed corticobasal syndrome, can result from various underlying pathologies including CBD, [PSP[/diseases/[psp[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX--, [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, and [frontotemporal lobar degeneration[/diseases/[frontotemporal-lobar-degeneration[/diseases/[frontotemporal-lobar-degeneration[/diseases/[frontotemporal-lobar-degeneration[/diseases/[frontotemporal-lobar-degeneration--TEMP--/diseases)--FIX--.
CBD typically presents in the sixth to seventh decade of life (mean age 63-68 years) and progresses to severe disability within 5-10 years. The disease is characterized by marked asymmetry of symptoms, with one side of the body affected significantly more than the other, distinguishing it from most other movement disorders.
¶ Epidemiology and Risk Factors
¶ Prevalence and Incidence
CBD is a rare neurodegenerative disorder:
- Estimated prevalence: 4-9 per 100,000 individuals
- Incidence: Approximately 0.6-0.9 per 100,000 person-years
- Age of onset: Typically 50-70 years (mean 63 years)
- Slight female predominance (1.2:1 female-to-male ratio)
- Most cases are sporadic, with less than 10% having a family history
The exact cause of CBD remains unknown:
- Genetic factors: Mutations in the [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- gene (microtubule-associated protein tau have been identified in some familial cases. The H1 haplotype of [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- is a risk factor for sporadic CBD
- Environmental factors: Some studies suggest associations with head trauma, but evidence remains inconclusive
- Age: The strongest risk factor, with almost all cases developing after age 50
- Other: There may be overlapping risk factors with PSP and Frontotemporal Dementia
CBD is classified as a 4-repeat (4R) tauopathy, characterized by:
- Neuronal loss and gliosis: Degeneration of cortical [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, particularly in the frontal and parietal lobes
- Ballooned [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (achromatic neurons): Swollen, eosinophilic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- with reduced staining (achromasia)
- Coiled bodies: Oligodendroglial inclusions containing hyperphosphorylated tau
- Astrogial plaques: Astrocytic tau inclusions
- Neuronal tau inclusions: Tangles and pretangles in affected [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
The tau pathology in CBD has a characteristic distribution:
- [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--: Frontoparietal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, especially the motor and premotor areas
- [Basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--: [Substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX--, globus pallidus, putamen
- [Brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX--: Red nucleus, subthalamic nucleus, locus coeruleus
- Motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--: Degeneration causes apraxia and weakness
- Premotor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--: Contributes to alien limb phenomena
- Somatosensory [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--: Causes cortical sensory loss
- [Basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--: [Substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- pars compacta (dopaminergic neuron loss), globus pallidus
- Corpus callosum: Wallerian degeneration contributing to interhemispheric disconnection
The mechanisms underlying neurodegeneration in CBD include:
- [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- dysfunction: Abnormal tau phosphorylation, misfolding, and aggregation
- Impaired axonal transport: Disruption of microtubule-based transport
- Synaptic dysfunction: Loss of synaptic connections
- neuroinflammation: Microglial activation
- Mitochondrial dysfunction: Energy metabolism defects
- Excitotoxicity: Excessive glutamate signaling
An important concept in CBD is that the clinical syndrome (corticobasal syndrome, CBS) can result from multiple underlying pathologies:
- Corticobasal Degeneration (classic 4R tauopathy): Most common cause
- [Progressive Supranuclear Palsy[/diseases/[psp[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX--: Can present as CBS
- [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: Up to 20% of CBS cases have AD pathology
- Frontotemporal lobar degeneration: FTLD-tau or FTLD-TDP
- Creutzfeldt-Jakob Disease: Rare cause of CBS presentation
The hallmark of CBD is marked asymmetry of symptoms:
- Akinesia and rigidity: Often beginning in one upper extremity
- Dystonia: Focal dystonia, often in the affected hand
- Myoclonus: Jerky, involuntary movements
- Alien limb phenomenon: Involuntary movement of a limb that feels foreign to the patient
- Apraxia: Impaired ability to perform purposeful movements, especially with the affected hand
- Cortical sensory loss: Impaired two-point discrimination, stereognosis, graphesthesia
- Alien limb: The affected limb seems to act independently of the patient's will
- Aphasia: Non-fluent or logopenic aphasia in some cases
- Constructional apraxia: Inability to copy or draw simple figures
- Limb apraxia: Inability to perform learned movements on command
- Executive dysfunction: Impaired planning, organization, problem-solving
- Memory deficits: Primarily retrieval difficulties
- Visuospatial dysfunction: Impaired spatial orientation
- Behavioral changes: Apathy, disinhibition
- Sensory symptoms: Numbness, tingling, pain in affected limb
- Speech impairment: Dysarthria, hypophonia
- Swallowing difficulties: Dysphagia
- Ocular motor abnormalities: Slow saccades, impaired smooth pursuit
- Cognitive decline: Progressive dementia
The typical progression of CBD:
- Onset: Asymmetric hand/limb symptoms (usually one side)
- Early progression: Spreads to ipsilateral leg within 1-2 years
- Bilateral involvement: Eventually affects both sides
- Late stage: Severe disability, falls, cognitive impairment
- End stage: Total care required, death typically within 6-10 years
[corticobasal degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration--TEMP--/diseases)--FIX-- (CBD) is a neuropathologic diagnosis defined by 4R tau pathology with astrocytic plaques and characteristic cortical/basal ganglia involvement,
while corticobasal syndrome (CBS) is a clinical phenotype defined by asymmetric motor-cortical dysfunction.[1][2]
In practical terms, patients can meet clinical CBS criteria but later prove to have non-CBD pathology (for example [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- or [Progressive Supranuclear Palsy[/diseases/[psp[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX--) at
autopsy. This distinction should be maintained in diagnostic language and counseling discussions.[2][4]
The diagnosis of CBD is clinical, based on the characteristic presentation of asymmetric cortical and basal ganglia features:
Core clinical features (required for probable CBD):
- Insidious onset and progressive course
- Age > 18 years
- Asymmetric presentation with at least one of:
- Limb rigidity or akinesia
- Limb dystonia
- Limb myoclonus
- Cortical sensory loss (two-point discrimination, stereognosis, graphesthesia)
- Alien limb phenomena
- Apraxia of the affected limb
- Constructional apraxia
Supportive features:
- Speech/language impairment (non-fluent aphasia)
- Cognitive impairment (executive dysfunction)
- MRI findings (asymmetric cortical atrophy, basal ganglia abnormalities)
- Brain MRI: Asymmetric frontoparietal atrophy, particularly in the precentral gyrus; atrophy of the basal ganglia
- FDG-PET: Hypometabolism in the affected hemisphere, particularly in the frontal and parietal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--
- DaTscan: May show dopaminergic deficit
- CSF biomarkers: May help exclude other conditions
| Condition |
Key Distinguishing Features |
| [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- |
Symmetric onset; resting tremor; levodopa responsive; no cortical features |
| PSP |
Vertical gaze palsy; early falls; symmetric; no cortical sensory loss |
| MSA |
Prominent autonomic failure; cerebellar signs in MSA-C |
| Alien limb (other causes) |
Usually related to stroke or tumor |
| Pick's Disease |
Behavioral changes prominent; language impairment |
| [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- |
Memory impairment early; symmetric presentation |
Motor symptoms:
- Levodopa: Often provides minimal or no benefit (distinguishing from PD)
- Dopamine agonists: May provide modest benefit in some cases
- Botulinum toxin injections: For focal dystonia
- Myoclonus: Clonazepam, valproic acid, or levetiracetam
Cognitive/behavioral symptoms:
- SSRIs: For depression and anxiety
- Cholinesterase inhibitors: May help cognitive symptoms
- Atypical antipsychotics: For severe behavioral disturbances (used cautiously)
Other symptoms:
- Dystonia: Muscle relaxants, botulinum toxin
- Pain: Neuropathic pain medications
- Physical therapy: Maintain range of motion, strength, and mobility
- Occupational therapy: Adaptive techniques, assistive devices for daily activities
- Speech therapy: For dysarthria and dysphagia
- Psychological support: Counseling for patient and family
- Home modifications: Safety modifications to prevent falls
- Anti-tau immunotherapy: Active and passive vaccination targeting tau protein
- Tau aggregation inhibitors: Small molecules to prevent tau aggregation
- Neuroprotective agents: Compounds targeting neuroinflammation
- Cell-based therapies: Stem cell approaches under investigation
The diagnosis of Corticobasal Degeneration (CBD) is primarily clinical, based on the characteristic combination of movement disorders and cognitive impairments. However, several diagnostic tools can support the clinical assessment and help rule out other conditions.
The Armstrong criteria (2013) are the most widely used for diagnosing CBD:
- Core features: Asymmetric parkinsonism, apraxia, cortical sensory loss, alien limb phenomenon
- Supportive features: Speech apraxia, ideomotor apraxia, cortical sensory deficits, alien limb
- Exclusion criteria: Presence of Lewy bodies, significant memory impairment early in disease
- MRI brain: May show asymmetric frontal and parietal atrophy, particularly in the precentral gyrus
- FDG-PET: Hypometabolism in the cortical regions corresponding to clinical deficits
- DaTscan: May show dopaminergic deficit, helping differentiate from essential tremor
- CSF analysis: May show elevated total tau protein in some cases
- Genetic testing: [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- mutations may be found in familial cases
There is currently no disease-modifying treatment for CBD. Management focuses on symptomatic relief and supportive care.
- Parkinsonism: Levodopa may provide modest benefit in some patients but is often ineffective
- Dystonia: Botulinum toxin injections can help manage focal dystonia
- Myoclonus: Antiepileptic drugs such as valproate, clonazepam, or levetiracetam may be tried
- Cognitive symptoms: Cholinesterase inhibitors may provide modest benefit for cognitive decline
- Physical therapy: Essential for maintaining mobility and preventing contractures
- Occupational therapy: Helps adapt to functional limitations and maintain independence
- Speech therapy: Addresses dysarthria and swallowing difficulties
- Psychological support: Important for managing depression and anxiety associated with the disease
- Tau-targeting therapies: Several clinical trials are investigating tau aggregation inhibitors and immunotherapy
- Neuroprotective agents: Research is ongoing to identify neuroprotective compounds
CBD has a poor prognosis similar to PSP:
- Mean survival from onset: 6-8 years
- Time to assisted walking: 3-5 years
- Time to severe disability: 5-7 years
- Time to nursing home placement: 4-6 years
Poor prognostic factors include:
- Early onset
- Rapid progression of symptoms
- Early cognitive impairment
- Presence of myoclonus
- Development of falls early in disease course
The study of Corticobasal Degeneration (Cbd) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following resources provide additional data on genes and proteins related to Corticobasal Degeneration (CBD):
The following questions are prioritized for near-term experimental and translational work. They are intended to guide hypothesis generation, preclinical design, and trial strategy.
- Which upstream mechanisms initiate asymmetric cortical and basal ganglia degeneration in [Corticobasal Degeneration (CBD)[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration--TEMP--/diseases)--FIX--?
- How can amyloid and tau PET profiles be integrated to distinguish AD-related [corticobasal syndrome[/diseases/[corticobasal-syndrome[/diseases/[corticobasal-syndrome[/diseases/[corticobasal-syndrome[/diseases/[corticobasal-syndrome--TEMP--/diseases)--FIX-- from true CBD pathology?
- What blood biomarker combinations best predict underlying neuropathology in clinically diagnosed corticobasal syndrome?
- How should language-led and cognitive-led CBS phenotypes be incorporated into next-generation diagnostic criteria?
- Which network-level imaging markers best track short-interval progression in CBD-focused clinical trials?
- How do [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/microglia
Corticobasal Degeneration represents a challenging neurodegenerative disorder that combines features of both parkinsonian and cortical syndromes. The heterogeneous clinical presentation, including asymmetric rigidity, apraxia, and cortical sensory loss, often leads to diagnostic delays and misdiagnosis. Neuropathologically, CBD is characterized by tau-positive inclusions in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and glia, with the 4-repeat tau isoforms playing a central role. Current management focuses on symptomatic treatment, with limited evidence for disease-modifying therapies. The development of tau PET imaging biomarkers and targeted immunotherapies offers hope for earlier diagnosis and more effective treatments. Multidisciplinary care including physical therapy, occupational therapy, and speech therapy remains essential for maintaining function and quality of life in affected individuals.
- Armstrong MJ, et al. Criteria for the diagnosis of Corticobasal Degeneration. Neurology. 2013;80(5):496-503. DOI:10.1212/WNL.0b013e31827f0fd1
- Lee SE, et al. Clinicopathological correlations in Corticobasal Degeneration. Neurology. 2011;77(6):589-595. DOI:10.1212/WNL.0b013e318228c3b4
- Bak TH, et al. Clinical, imaging and pathological correlates of Corticobasal Degeneration. Brain. 2006;129(Pt 5):1185-1198. DOI:10.1093/brain/awl071
- Boeve BF, et al. Corticobasal Degeneration and Frontotemporal Dementia presentations in a patient with underlying [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- pathology. Neurocase. 2005;11(4):273-282. DOI:10.1080/1355479050022935
- Hassan A, et al. Neuropathologic basis of Frontotemporal Dementia in Corticobasal Degeneration. Acta Neuropathol. 2010;119(3):365-379. DOI:10.1007/s00401-009-0615-z
- Kouri N, et al. Corticobasal Degeneration with olivopontocerebellar atrophy: a new subtype? Acta Neuropathol. 2015;129(1):65-79. DOI:10.1007/s00401-014-1353-4
- Murray R, et al. Neuropathology of Corticobasal Degeneration: comparison with Progressive Supranuclear Palsy and [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--. J Neurol Neurosurg Psychiatry. 2015;86(9):1012-1020. DOI:10.1136/jnnp-2014-307786## See Also## External Links
-
-
-
pie title Disease Prevalence (per 100,000)
"Prevalence": 1000
"Annual Incidence": 50
| Metric |
Value |
| Global Prevalence |
~6.5 million |
| Age of Onset |
65 years |
| Progression Rate |
Moderate |
timeline
title Disease Progression
Preclinical : Risk Factors
: Biomarker Changes
Early : Mild Symptoms
: Diagnosis
Moderate : Motor/Cognitive Decline
: Treatment Initiation
Advanced : Severe Disability
: Care Requirements
## See Also
- [Neurodegenerative Diseases)
- [Diseases Index)
- [All Pages)
## External Links
- [National Institute of Neurological Disorders and Stroke](https://www.ninds.nih.gov/health-information/disorders/corticobasal-degeneration)
- [NHS: Corticobasal Degeneration](https://www.nhs.uk/conditions/corticobasal-degeneration/)
- [Orphanet: Corticobasal Degeneration](https://www.orpha.net/en/disease/detail/228252)
- [PubMed - CBD Research](https://pubmed.ncbi.nlm.nih.gov/?term=corticobasal+degeneration)
- [ClinicalTrials.gov - CBD Trials](https://clinicaltrials.gov/search?cond=Corticobasal+Degeneration)
- [NINDS Corticobasal Degeneration Information](https://www.ninds.nih.gov/health-information/disorders/corticobasal-degeneration)